BIOPHYTIS Aktie

>BIOPHYTIS Performance

1 Woche: -98,0%

1 Monat: -99,7%

3 Monate: -99,9%

6 Monate: -99,9%

1 Jahr: -99,9%

laufendes Jahr: -99,9%

>BIOPHYTIS Aktie

Name:

BIOPHYTIS NAM. EO -,002

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR001400OLP5 / A403QV

Symbol/ Ticker:

6XB3 (Frankfurt)

Kürzel:

FRA:6XB3, ETR:6XB3, 6XB3:GR

Index:

Webseite:

https://www.biophytis.com..

Profil:

Biophytis S.A. is a clinical-stage biotechnology company that is primarily focused on developing therapies for age-related diseases and chronic conditions. Headquartered in Paris, France, and with operations extending to the United States, Biophytis ..
>Volltext..

Marktkapitalisierung:

1.54 Mio. EUR

Unternehmenswert:

Umsatz:

EBITDA:

Nettogewinn:

Gewinn je Aktie:

Schulden:

Liquide Mittel:

Operativer Cashflow:

Bargeldquote:

Umsatzwachstum:

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

BIOPHYTIS

Letzte Datenerhebung:

05.04.26

>BIOPHYTIS Kennzahlen

Aktien/ Unternehmen:

Aktien: 91.62 Mio. St.

Frei handelbar: 95.47%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 20

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 200%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -

Eigenkaprendite: -

>BIOPHYTIS Peer Group

Gesundheit

>BIOPHYTIS Chart & Kurs - Stuttgart

>BIOPHYTIS News

16.03.26 - 12:00	Biophytis and LynxKite expand alliance to boost AI-driven drug discovery (PBR)
	Supported by Enterprise Singapore, the initiative aims to enhance Biophytis' computational longevity platform and develop therapies for age-related diseases such as sarcopenia. The collaboration builds on Biophytis' ongoing The post Biophytis and LynxKite expand alliance to boost AI-driven drug discovery appeared first on Pharmaceutical Business review....

13.03.26 - 16:42	Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics (PR Newswire)
	Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies This partnership will generate revenue through: A computational longevity platform, including unique curated datasets and accelerated computation methods relevant......

14.07.25 - 09:45	XFRA: 6XB3: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIOPHYTIS NAM. EO -,10 6XB3 FR001400OLP5 AB/FROM ONWARDS 14.07.2025 09:39 CET...

17.06.25 - 11:31	XFRA: INSTRUMENT_SUSPENSION - EQUBF_01 (XETRA)
	Instrument ID [19470526] (6XB3 - FR001400OLP5) suspended...

17.06.25 - 11:31	XFRA: 6XB3: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL BIOPHYTIS NAM. EO -,10 6XB3 FR001400OLP5 BAW/UFN...

22.04.25 - 07:06	Biophytis Targets Mobility Restoration in Patients with Obesity (Newsfile)
	Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 22, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in dev......

09.04.25 - 07:42	Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity (Newsfile)
	Paris, France and Cambridge, Massachusetts--(Newsfile Corp. - April 9, 2025) - Biophytis SA (FP: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the ......

24.03.25 - 07:48	Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity (Newsfile)
	96% of patients with obesity report experiencing muscle strength impairment, affecting their mobilityNew preclinical study results: The combination of BIO101 and GLP-1 induced muscle strength and ......

17.03.25 - 07:12	Biophytis Revolutionizes Sarcopenia (Newsfile)
	Publication of SARA-INT Phase II results for BIO101Confirmation of Phase 3 readinessParis, France and Cambridge, Massachusetts--(Newsfile Corp. - March 17, 2025) - Biophytis SA (FP: ALBPS) ("Bioph......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram